Simply Better Brands Corp, Growing 359% vs Year Ago Preliminarily Sales Results Year to Date, Announces Its Trubar Brand’s Accelerated Expansion of Its Portfolio and Distribution

2 years ago

Women-founded, Women-led Nutrition Brand Expands Dessert-inspired, Plant-Based brand in flavor innovation, category expansion and retail footprint TRUBAR 2021 vs 2022…

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022

2 years ago

--- Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological EndpointsWALTHAM, Mass., Oct. 19, 2022…

Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio

2 years ago

Brings total to twelve granted patents across the Company’s full portfolio LONDON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Small Pharma…

Nephros Third Quarter 2022 Financial Results Conference Call

2 years ago

SOUTH ORANGE, NJ, Oct. 19, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology…

Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022

2 years ago

Highlighting Ocugen research and innovative technologies Featuring thought leaders in gene therapy and vaccines MALVERN, Pa., Oct. 19, 2022 (GLOBE…

Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

2 years ago

NEW YORK and CLEVELAND, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the database lock…

Sinaptica Therapeutics Announces FDA Breakthrough Device Designation for its Novel Noninvasive Neurostimulation Treatment for Alzheimer’s Disease

2 years ago

SinaptiStim™ – AD System provides personalized and precision-delivered electromagnetic therapeutic approach to treating cognitive and functional decline in Alzheimer’s disease…

Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022

2 years ago

BEDMINSTER, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused…

Miromatrix CEO Jeff Ross Delivering Keynote Address at ARMI | BioFabUSA 2022 Fall Summit: Meeting in the Millyard

2 years ago

EDEN PRAIRIE, Minn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a…

Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

2 years ago

BOSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering…